{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-160387","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.403823+00:00","generated_at":"2026-06-14T07:38:34.513000+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Phoenix Biotech Acquisition Corp. to merge with CERo Therapeutics in $50M deal","bullets":["Consideration: ~5.0M shares of Class A common stock (value ~$50M) for CERo holders, plus up to 1.2M earnout shares.","Closing condition: available cash after redemptions must be at least $30M; termination date Sept 30, 2023, extendable.","Sponsor (699,996 Class A and 4,596,250 Class B shares) and CERo stockholders entered support agreements to vote in favor.","Combined company renamed to 'CERo Therapeutics Holdings, Inc.' and will apply to list on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-160387","json":"https://secwatch.observer/filing/0001193125-23-160387.json","markdown":"https://secwatch.observer/filing/0001193125-23-160387.md","text":"https://secwatch.observer/filing/0001193125-23-160387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/0001193125-23-160387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/d494471d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:38:34.513000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad90f2ebafe930673a98d51ba550de091f121481","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Business Combination Agreement with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., and CERo Therapeutics, Inc. (effective 2023-06-04).","evidence_excerpt":"On June 4, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), entered into a business combination agreement and plan of reorganization (the “ Business Combination Agreement ”), by and among the Company, PBCE Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and CERo Therapeutics, Inc., a Delaware corporation (“ CERo ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/0001193125-23-160387-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., and CERo Therapeutics, Inc."},{"label":"Effective","value":"2023-06-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}